CD8A and neoplasm: Using anti-TREM2 monoclonal antibodies drives robust anti-tumor immunity by increasing CD8+ tumor-infiltrating lymphocytes (TILs) infiltration and enhancing their effector function in glioblastoma ovarian cancer 22, 23.